

Monika Hiller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8818364/publications.pdf>

Version: 2024-02-01

9

papers

308

citations

1478505

6

h-index

1474206

9

g-index

9

all docs

9

docs citations

9

times ranked

587

citing authors

#	ARTICLE	IF	CITATIONS
1	TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy. European Journal of Human Genetics, 2020, 28, 815-825.	2.8	36
2	The mRNA Binding Proteome of Proliferating and Differentiated Muscle Cells. Genomics, Proteomics and Bioinformatics, 2020, 18, 384-396.	6.9	5
3	Premature termination codons in the <i>DMD</i> gene cause reduced local mRNA synthesis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16456-16464.	7.1	30
4	A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures. PLoS ONE, 2018, 13, e0204485.	2.5	14
5	Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice. Methods in Molecular Biology, 2018, 1828, 249-262.	0.9	4
6	Cytokine Profiling of Serum Allows Monitoring of Disease Progression in Inclusion Body Myositis. Journal of Neuromuscular Diseases, 2017, 4, 327-335.	2.6	8
7	Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy. Molecular Therapy - Nucleic Acids, 2015, 4, e265.	5.1	20
8	Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing <i>SPP1</i> and <i>LTBP4</i> variants. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1060-1065.	1.9	86
9	Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies. EMBO Molecular Medicine, 2014, 6, 918-936.	6.9	105